clinical trial · NCT03843892
An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
Boehringer Ingelheim·—·approved for marketing
Lung Diseases, InterstitialOFEV
brief summary
This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.
started
—
primary completion
—
completion
—
last updated
Dec 10, 2024
official title
Expanded Access Use of OFEV (Nintedanib) in Non-IPF Interstitial Lung Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol